Key Highlights
- Aleniglipron, Structure Therapeutics’ oral GLP-1 medication, demonstrated 16.3% placebo-adjusted weight reduction after 44 weeks in the ACCESS II Phase 2 study
- The data outperformed oral GLP-1 competitors from Novo Nordisk (13.6% weight loss) and Eli Lilly (12.4% in Phase 2)
- The treatment demonstrated continued efficacy without plateauing, distinguishing it from competing therapies
- Shares of GPCR climbed approximately 10% on Monday, reaching $59.80 following the announcement
- The company has scheduled an end-of-Phase 2 FDA consultation for Q2 2026, with Phase 3 trials starting in H2 2026
Structure Therapeutics unveiled compelling Phase 2 clinical data for aleniglipron, its oral GLP-1 candidate, on Monday, propelling GPCR shares up roughly 10% during morning trading hours.
Structure Therapeutics Inc., GPCR
The ACCESS II clinical study demonstrated 16.3% placebo-adjusted weight reduction at the 180 mg dosage level and 16.0% at the 240 mg level following 44 weeks of treatment. Importantly, both dosages continued showing efficacy gains without reaching a plateau.
These figures compare favorably against competitive programs. Novo Nordisk’s oral Wegovy formulation delivered 13.6% weight loss during Phase 3 testing. Eli Lilly’s orforglipron achieved approximately 12.4% in Phase 2 trials, with 11.2% recorded in Phase 3.
Previous data released in December had demonstrated 14.2% weight loss at a lower dose level. Participants who remained on this reduced dose for 53 weeks ultimately achieved 16% weight reduction, suggesting sustained therapeutic benefit over extended treatment periods.
The safety and tolerability profile remained favorable. Within the ACCESS Open Label Extension trial, only 2% of participants discontinued due to adverse events. The body composition analysis showed a 3.4% discontinuation rate. Structure’s approach of initiating treatment at a low 2.5 mg dose appears to contribute to improved patient adherence.
The positive results have sparked acquisition speculation. H.C. Wainwright analyst Ananda Ghosh had previously identified aleniglipron this month as “the most acquirable asset in obesity.” The firm increased its price target to $114. Citizens maintained a Market Outperform rating while adjusting its target to $113.
Wall Street Perspectives
Leerink Partners reaffirmed its Outperform rating alongside a $90 price target following the data release. The firm emphasized the favorable tolerability profile and clear dose-response correlation as significant advantages.
RBC Capital Markets adopted a more cautious stance. Analyst Trung Huynh observed that orforglipron demonstrated comparable Phase 2 results before showing weaker Phase 3 outcomes. He identified an atypically low weight gain rate in the placebo cohort as a statistical anomaly requiring further scrutiny. RBC maintained its Outperform rating on Lilly with a $1,250 price target.
“It’s difficult to characterize these results as meaningfully differentiated from Orfo or oral Wegovy until we get a more robust data set,” Huynh wrote.
Future Timeline
Structure has scheduled an end-of-Phase 2 regulatory meeting with the FDA for Q2 2026. Phase 3 clinical trials are anticipated to commence during the second half of 2026. The company will leverage Phase 2 data from both high-dose cohorts to determine the optimal dosage for advanced development.
Despite Monday’s gains, the stock remains down 23% year-to-date entering the session, though it has surged 155% over the trailing twelve months. At $59.80, GPCR trades significantly below Wall Street consensus targets, which span from $90 to $140.
Cantor Fitzgerald had previously identified this 44-week data readout as a potential stock catalyst. That projection materialized as anticipated.
Monday’s rally elevated GPCR’s market capitalization to roughly $3.81 billion.
